United Tech (UTX) Offering Possible 104.92% Return Over the Next 24 Calendar Days

United Tech's most recent trend suggests a bearish bias. One trading opportunity on United Tech is a Bear Call Spread using a strike $125.00 short call and a strike $130.00 long call offers a potential 104.92% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $125.00 by expiration. The full premium credit of $2.56 would be kept by the premium seller. The risk of $2.44 would be incurred if the stock rose above the $130.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for United Tech is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for United Tech is bearish.

The RSI indicator is at 45.15 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for United Tech

RBC Capital: 5 New Stocks Hedge Funds Snapped Up In Q2
Sun, 25 Aug 2019 09:35:51 +0000
Hedge funds have just released their portfolio trades for the second quarter. And now is the time to evaluate these trades for valuable investing insights. Here we focus on one particular aspect of hedge fund activity- new stock additions. That’s using an August 19 report from RBC Capital which analyzes the 2Q19 13f forms of 363 major hedge funds with significant stakes in US equities (single stocks). The firm used this data to pinpoint the top stocks where hedge fund ownership rose the most during 2Q19, in terms of the net number of funds that added new positions.Three names fall in Health Care (including the 1 name- Allergan (AGN)). Another three names fall in Industrials, notes the firm. But there is one key stock worth bearing in mind: “Note that UBER (UBER) does not qualify for this screen as it does not fall in the S&P 500 and it began trading mid way through the 2nd quarter. It was owned by 51 hedge funds at the end of 2Q19” points out the firm.With that being said, let’s take a closer look at five top new stocks hedge funds are making a bet on right now: 1\. Align Technology (ALGN)Align Technology is leading an orthodontics revolution. The company invented the Invisalign- a clear teeth aligner system- that can replace traditional braces. In Q2, 14 new funds bought Align shares- bringing the total value of ALGN shares owned by hedge funds to $1,805 million. Unfortunately however the stock has declined in both Q2 and Q3. Despite strong Q2 earnings results, the company’s guidance left investors disappointed. "Given the uncertainty in China," CEO Joe Hogan commented, "our outlook for the third quarter reflects a more cautious view for growth in the Asia Pacific region."Don’t be disheartened, says Piper Jaffray’s Matthew O’Brien. This five-star analyst has just reiterated his ALGN buy rating with a $240 price target (37% upside potential). Align "has much better products that will win in the marketplace" he tells investors. O’Brien believes that an accelerated stock repurchase plan of $200 million demonstrates confidence in Align’s outlook.Overall, ALGN shows a Moderate Buy analyst consensus, with an average price target of $259. Interestingly if we look at only the best-performing analysts, this consensus shifts to Strong Buy. 2\. Qualcomm (QCOM)Chip titan Qualcomm is an intriguing hedge fund pick. In the second quarter, 20 more funds owned QCOM stock vs the first quarter. As a result, 15% of the funds covered in RBC Capital’s study now own Qualcomm. Their total holding works out at $1,682 million.Despite numerous problems- most obviously the May 21 antitrust ruling – some analysts do see a bright future ahead. That’s thanks to the company’s prime 5G position. “We believe Qualcomm's bull case is unchanged, with global 5G roll outs expected to increase both royalty income and demand for semiconductors beginning in 2020,” Merrill Lynch’s Tal Liani said recently. “Press reports suggest that all of Apple's 2020 iPhones will contain Qualcomm's 5G chipset, which could drive a 5G cycle across the entire industry.” The analyst has just reiterated his QCOM buy rating and $100 price target (36% upside potential). No doubt hedge funds are also relieved to hear that Qualcomm has just won a critical partial stay from The Ninth Circuit Court of Appeals. The company won’t have to grant patent licenses to rivals and can still require patent licenses for customers to buy chips while its appeal is ongoing. According to Qualcomm general counsel Don Rosenberg, the company still believes “the district court decision will be overturned once the merits of our appeal have been considered.” In total, QCOM scores a Moderate Buy Street consensus with a $78 average price target. 3\. Hologic (HOLX)Medical tech stock Hologic focuses primarily on women’s health and beauty; it sells medical devices for surgery and medical imaging. During Q2, 14 funds initiated positions in HOLX. RBC Capital reveals that funds now own a total of $748 million in Hologic stock. Of course, Hologic has a history when it comes to hedge funds. Back in 2013, hedge fund activist Carl Icahn swooped in with a 12.63% stake. Three years later he cashed in on what proved to be a successful intervention. “Yesterday our designees resigned from the [Hologic] board because the situation no longer calls for activism,” Icahn wrote on Twitter at the time. “Hologic is the quintessential example of activism at its best. We commend [Hologic chief executive] Steve MacMillan for a job well done.”Looking ahead, analysts are divided over HOLX’s outlook. Five analysts currently rate the stock a buy, while four analysts are staying on the sidelines. “Hologic is gradually executing over the course of this year as its breast health and molecular diagnostics businesses pace its growth, but are offset by slower growth or declining segments” states Canaccord Genuity’s Mark Massaro. This Top 50 analyst reiterated his hold rating on Hologic on August 1, but ramped up the price target from $49 to $52 (8% upside potential). “Near mid-single-digit growth and effective capital allocation (buybacks and tuck-in deals) are warming us up to the stock as HOLX delivered a 2% top-line beat, 2 cent bottom-line beat, and raised its FY top- and bottom-line guide” he explained. 4\. United Technologies Corp (UTX)Like the previous two stocks, United Technologies Corp saw the addition of 14 new funds in Q2. This aerospace and defense stock now features in 16% of the portfolios scanned by RBC Capital. And the total hedge fund holding is valued at $4,552 million.Encouragingly, analysts are positive on UTX right now. The stock boasts a ‘Strong Buy’ consensus, and a price target that indicates 23% upside from current levels. Indeed, both Vertical Research and Seaport Global upgraded United Technologies from Hold to Buy in the last couple of months.The analysts made their calls after the news of a proposed $120 billion merger between UTX and Raytheon (RTN) sent shares plummeting. The deal, which is set to close in the first half of the year, is currently undergoing an investigated by the U.S. Department of Justice’s antitrust division. According to Vertical Research analyst Jeffrey Sprague the stock’s weakness created an attractive buying opportunity.More recently, five-star Cowen & Co analyst Cai Rumohr reiterated his UTX buy rating and $150 price target. Turning the cash flow corner, enthused Rumohr following Q2 earnings. “Q2's EPS/cash flow beat suggests cash consuming build in new aerospace programs is starting to reverse with a likely multi-year ramp in standalone CFPS [cash flow per share]. And the proposed RTN merger would accelerate cash deployment potential” summed up the analyst. 5\. Roper Technologies (ROP) Roper Technologies is a diversified industrial company that produces engineered products for global niche markets. That includes everything from creative software technologies for visual effects and 3D content, to safety valves and radiotherapy solutions. Thirteen hedge funds started new positions in Roper during Q2, says RBC Capital.Indeed, the firm’s own Deane Dray shares this bullish outlook on Roper stock. He recently reiterated his buy rating while bumping up the price target from $391 to $393 (13% upside potential). “Outperform-rated Roper’s modest 2Q19 beat featured its typical high quality of earnings” Dray wrote post-earnings. However, the analyst added that there was a pang of disappointment with the disclosure that expected 2H19 slowing in short- cycle industrial businesses (8% of revenues) could pose a -10c headwind. Ultimately, though, Roper remains “indisputably one of the highest-quality names within the Multi-Industry sector.” It leads the pack in EBIT margin and free cash flow conversion thanks to its portfolio of low- capital-intensity and profitable SaaS and network businesses, he tells investors. Currently five analysts rate ROP a buy, with only 1 analyst calling the stock a hold- giving it a ‘Strong Buy’ consensus. Meanwhile the average analyst price target stands at $399 suggesting shares can climb 15% in the coming months. Find analysts' favorite stocks with the Top Analysts' Stocks tool

Raytheon, McKinney finalizing incentive agreement for new factory
Fri, 23 Aug 2019 12:56:48 +0000
When Raytheon examined customer demand within its Space and Airborne Systems business unit, headquartered in McKinney, company leadership realized their current capacity wasn't going to be enough. The new plant, which doesn't have a name yet, will be the first new building on the McKinney campus since 2001, said Roy Azevedo, president of SAS. “We see the community as being committed to Raytheon Company and working with Raytheon,” said Azevedo, adding that the sentiment “goes both ways.” The McKinney Economic Development Corporation board of directors approved an incentive package for Raytheon's expansion, said Peter Tokar, president and chief executive of the MEDC, adding the two sides are finalizing negotiations.

Why Is United Technologies (UTX) Down 5.2% Since Last Earnings Report?
Thu, 22 Aug 2019 13:30:01 +0000
United Technologies (UTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Honeywell (HON) Strengthens Forge for Buildings Platform
Thu, 22 Aug 2019 13:30:01 +0000
Honeywell's (HON) suite of solutions uses IoT connectivity, interoperable systems and data sharing, as well as adaptive workflows to convert inputs and information into actionable insights.

Ackman Calls Berkshire Misunderstood, Sees Big Returns
Mon, 19 Aug 2019 13:45:57 +0000
During its latest 13F filings, Bill Ackman’s Pershing Square Holdings revealed its new stake in Warren Buffett’s Berkshire Hathaway.

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.